Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Liabilities and Shareholders Equity (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Liabilities and Shareholders Equity for 6 consecutive years, with $79.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 1718.52% to $79.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $361.3 million, a 831.78% increase, with the full-year FY2024 number at $98.6 million, up 579.69% from a year prior.
  • Liabilities and Shareholders Equity was $79.6 million for Q3 2025 at Inhibikase Therapeutics, down from $88.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $98.6 million in Q4 2024 to a low of $4.4 million in Q3 2024.
  • A 5-year average of $39.1 million and a median of $28.6 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: tumbled 75.52% in 2024, then soared 1718.52% in 2025.
  • Inhibikase Therapeutics' Liabilities and Shareholders Equity stood at $42.5 million in 2021, then crashed by 41.28% to $24.9 million in 2022, then plummeted by 41.83% to $14.5 million in 2023, then surged by 579.69% to $98.6 million in 2024, then dropped by 19.28% to $79.6 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Liabilities and Shareholders Equity are $79.6 million (Q3 2025), $88.9 million (Q2 2025), and $94.3 million (Q1 2025).